ANAPTYSBIO, INC. Net Income (Loss) Available to Common Stockholders, Basic
ANAPTYSBIO, INC. (ANAB) reported Net Income (Loss) Available to Common Stockholders, Basic of -$20.26 million for the 3-month period ending 2019-12-31, per its 10-K filed 2020-03-02.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2020-03-02
- ANAPTYSBIO, INC. net income (loss) available to common stockholders, basic for the quarter ending 2019-12-31 was -$20.26M.
- ANAPTYSBIO, INC. net income (loss) available to common stockholders, basic for the quarter ending 2019-09-30 was -$31.03M.
- ANAPTYSBIO, INC. net income (loss) available to common stockholders, basic for the quarter ending 2019-06-30 was -$23.96M.
- ANAPTYSBIO, INC. net income (loss) available to common stockholders, basic for the quarter ending 2019-03-31 was -$22.08M.
- ANAPTYSBIO, INC. net income (loss) available to common stockholders, basic for fiscal 2019 was -$97.34M.
- ANAPTYSBIO, INC. net income (loss) available to common stockholders, basic for fiscal 2018 was -$61.66M.
- ANAPTYSBIO, INC. net income (loss) available to common stockholders, basic for fiscal 2017 was -$30.07M.
- ANAPTYSBIO, INC. net income (loss) available to common stockholders, basic for fiscal 2016 was -$4.26M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|---|
| 2019-12-31 | -$20.26M 10-K · filed 2020-03-02 | -$51.30M derived: sum of 2 quarters · filed 2020-03-02 | -$75.26M derived: sum of 3 quarters · filed 2020-03-02 | -$97.34M 10-K · filed 2020-03-02 | |
| 2019-09-30 | -$31.03M 10-K · filed 2020-03-02 | -$54.99M derived: sum of 2 quarters · filed 2020-03-02 | -$77.07M derived: sum of 3 quarters · filed 2020-03-02 | -$94.07M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2019-06-30 | -$23.96M 10-K · filed 2020-03-02 | -$46.04M derived: sum of 2 quarters · filed 2020-03-02 | -$63.03M derived: sum of 3 quarters · filed 2020-03-02 | -$78.99M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2019-03-31 | -$22.08M 10-K · filed 2020-03-02 | -$39.07M derived: sum of 2 quarters · filed 2020-03-02 | -$55.03M derived: sum of 3 quarters · filed 2020-03-02 | -$68.65M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2018-12-31 | -$16.99M 10-K · filed 2020-03-02 | -$32.95M derived: sum of 2 quarters · filed 2020-03-02 | -$46.57M derived: sum of 3 quarters · filed 2020-03-02 | -$61.66M 10-K · filed 2020-03-02 | |
| 2018-09-30 | -$15.96M 10-K · filed 2020-03-02 | -$29.58M derived: sum of 2 quarters · filed 2020-03-02 | -$44.66M derived: sum of 3 quarters · filed 2020-03-02 | -$51.52M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2018-06-30 | -$13.62M 10-K · filed 2020-03-02 | -$28.70M derived: sum of 2 quarters · filed 2020-03-02 | -$35.56M derived: sum of 3 quarters · filed 2020-03-02 | -$44.66M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2018-03-31 | -$15.09M 10-K · filed 2020-03-02 | -$21.95M derived: sum of 2 quarters · filed 2020-03-02 | -$31.04M derived: sum of 3 quarters · filed 2020-03-02 | -$33.72M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2017-12-31 | -$6.86M 10-K · filed 2019-02-28 | -$15.95M derived: sum of 2 quarters · filed 2019-02-28 | -$18.64M derived: sum of 3 quarters · filed 2019-02-28 | -$30.07M 10-K · filed 2020-03-02 | |
| 2017-09-30 | -$9.09M 10-K · filed 2019-02-28 | -$11.77M derived: sum of 2 quarters · filed 2019-02-28 | -$23.21M 10-Q · filed 2017-11-07 | -$27.79M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2017-06-30 | -$2.68M 10-K · filed 2019-02-28 | -$14.12M 10-Q · filed 2017-08-10 | -$18.70M derived: sum of 3 quarters · filed 2019-02-28 | -$19.81M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2017-03-31 | -$11.44M 10-K · filed 2019-02-28 | -$16.01M derived: sum of 2 quarters · filed 2019-02-28 | -$17.13M derived: sum of 3 quarters · filed 2019-02-28 | -$14.81M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2016-12-31 | -$4.58M 10-K · filed 2018-03-05 | -$5.69M derived: sum of 2 quarters · filed 2018-03-05 | -$3.37M derived: sum of 3 quarters · filed 2018-03-05 | -$4.26M 10-K · filed 2018-03-05 | |
| 2016-09-30 | -$1.11M 10-K · filed 2018-03-05 | $1.21M derived: sum of 2 quarters · filed 2018-03-05 | $0.00 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | $2.32M 10-K · filed 2018-03-05 | $181.00K 10-Q · filed 2017-08-10 | $0.00 10-Q · filed 2017-08-10 | ||
| 2016-03-31 | -$888.00K 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |